Introduction MUC1 (MUC1 in humans, Muc1 in mice) is the founding member of a large and evolutionarily conserved family of proteins known as mucins (Gendler and Spicer, 1995; Gendler, 2001; Hollingsworth and Swanson, 2004) . Mucins are broadly defined as proteins with extensive O-linked glycosylation, which constitutes 50% of the total molecular mass. MUC1 is a transmembrane mucin with a large, heavily glycosylated extracellular domain and a highly conserved cytoplasmic tail. It is normally expressed on the apical surface of most simple secretory epithelia and several hematopoietic cell lineages (Gendler, 2001) .
MUC1 was initially cloned from mammary and pancreatic carcinomas as a tumor antigen (Gendler et al., 1987 (Gendler et al., , 1990 Lan et al., 1990; Ligtenberg et al., 1990; Wreschner et al., 1990) . More than 90% of human breast cancers overexpress aberrantly glycosylated MUC1 (Zotter et al., 1988) . In cancer cells, the pattern of MUC1 expression is altered such that it is no longer restricted to the apical surfaces; instead, it is expressed intracellularly and around the entire cell surface . Accumulating evidence suggests a functional role for MUC1 in transformation. It has been suggested that MUC1 contributes to tumor progression by functioning as an antiadhesive molecule, thereby destabilizing cell-cell and cell-matrix connections (Wesseling et al., , 1996 . Other findings suggest that MUC1 acts as a proadhesive molecule, facilitating the metastatic process by allowing migrating cells to reattach (Regimbald et al., 1996; Kam et al., 1998) . Additionally, numerous observations point to a role for MUC1 in signal transduction. The 72-aminoacid tail of MUC1 contains seven tyrosines, six of which are 100% conserved across mammalian species (Spicer et al., 1995a) . The cytoplasmic tail of MUC1 is phosphorylated on tyrosine residues in epithelial cell lines and mouse mammary glands; it contains potential docking sites for SH2-containing proteins and several kinase recognition sites (Zrihan-Licht et al., 1994; Mockensturm-Gardner and Gendler, 1998; Schroeder et al., 2001) . Indeed, MUC1 cytoplasmic tail interacts with a variety of proteins involved in neoplasia and cell adhesion such as EGFR, erbB2, erbB3, erbB4, PKCd, Grb2, GSK3b, and p120 ctn (Pandey et al., 1995; Yamamoto et al., 1997; Li et al., 1998 Li et al., , 2001a Li and Kufe, 2001; Schroeder et al., 2001; Ren et al., 2002) . Yet in spite of MUC1 being recognized as a tumor-associated antigen, its precise function in tumorigenesis and disease progression remains elusive.
As mentioned above, c-Src is among the oncogenic proteins that interact with the cytoplasmic tail of MUC1 (Li et al., 2001a, b) . c-Src is a well-characterized nonreceptor tyrosine kinase implicated in mammary tumorigenesis. c-Src is located within adhesion plaques and at cadherin-mediated cell-cell junctions in epithelial cells (Jones et al., 2000) . Aberrant activation of c-Src tyrosine kinase is a characteristic of a large proportion of human breast carcinomas (Ottenhoff-Kalff et al., 1992) . High levels of c-Src result in the activation of multiple mitogenic signaling pathways including the Ras/MAPK pathway (Penuel and Martin, 1999) . Figure 9 depicts the cellular effects downstream of cSrc activation promoting growth, mitogenesis, survival, and migration. Previous in vitro studies have shown that MUC1 interacts with the c-Src tyrosine kinase, whereby c-Src phosphorylates the MUC1 cytoplasmic domain at a YEKV motif (Li et al., 2001a) .
It is believed that MUC1 competes with E-cadherin for b-catenin binding and therefore is involved in disrupting cell adhesion complexes (Ligtenberg et al., 1992; Wesseling et al., 1995) . Previously, it has been shown that, in vitro, b-catenin interacts with MUC1 at an SXXXXXSSL site present in the cytoplasmic tail of MUC1 (Yamamoto et al., 1997) . GSK3b also has been shown to bind directly to MUC1 at a DRSPY site adjacent to that for b-catenin, hence decreasing the interaction of MUC1 with b-catenin (Li et al., 1998) . On the other hand, the interaction between MUC1 and c-Src results in the phosphorylation of MUC1 at the YEKV motif located between sites involved in interactions with GSK3b and b-catenin. Phosphorylation of MUC1 provides a binding site for c-Src SH2 domain, and in turn inhibits the interaction between MUC1 and GSK3b (Li et al., 2001a) . Therefore, inhibition of the association of MUC1 with GSK3b increases the binding of MUC1 and b-catenin.
A better understanding of the function of MUC1 in tumorigenesis has been derived from transgenic and knockout mouse models. Lack of Muc1 expression leads to a significant delay in tumor onset in the mouse mammary tumor virus (MMTV)-Wnt-1 mouse model of breast cancer, suggesting that Muc1 is involved in the initiation stages of cancer in that b-catenin-dependent model (Schroeder et al., 2003) . We have recently shown that MUC1 overexpression promotes in vivo transformation of the mammary gland, establishing that MUC1 is not merely a by-product of transformation but can itself promote transformation in a physiological context (Schroeder et al., 2004) . To elucidate the role of MUC1 in tumor progression and metastasis, we crossed MMTV-driven polyoma middle T-antigen (MMTVPyV MT) transgenic mice onto a Muc1 null background (Spicer et al., 1995b) . While MMTV-PyV MT transgenic mice developed multifocal mammary tumors with a high frequency of lung metastasis (Guy et al., 1992) , tumor progression was significantly delayed in Muc1 null/ MMTV-PyV MT transgenics (Spicer et al., 1995b) . The high transforming activity of the PyV MT antigen is dependent on the interaction of the PyV MT with the Src family of kinases (c-Src, c-Yes, and Fyn), and it has been shown that activation of c-Src is essential for the induction of mammary tumors in the MMTV-PyV MT transgenic mice (Guy et al., 1994) . The delayed mammary tumor progression in the MMTV-PyV MT transgenic mice lacking Muc1 and the functional interaction between MUC1 and c-Src suggest a signaling role for Muc1 in MMTV-PyV MT tumorigenesis. We hypothesize that MUC1 is an important contributor to transformation and functions as a target for oncogenic kinases and signaling proteins.
The MMTV-PyV MT mouse model is used to develop a better understanding of the signaling role of Muc1 in tumorigenesis. The MMTV-PyV MT model has proven invaluable in dissecting the signal transduction pathways that are altered during mammary gland transformation. PyV MT antigen lacks intrinsic biochemical activity, yet it exerts its oncogenic potential by hijacking the normal regulatory pathways that govern cellular proliferation and survival. PyV MT modulates the activities of a variety of key regulatory proteins such as phosphatase 2A, tyrosine kinases of the Src family, phosphatidylinositol 3-kinase (PI3K), Shc, and phospholipase C-g1 (PLC-g1) (Dilworth, 1995) .
In this study, we examined the effect of Muc1 expression on c-Src signaling in the MMTV-PyV MT model in an effort to discern the mechanism for the delay in tumor progression that is observed in the absence of Muc1. We identified an in vivo association between Muc1 and c-Src in the PyV MT-induced mammary tumors. We show that Muc1 expression promotes the interaction of c-Src with key signaling proteins and affects downstream Src signaling as suggested in the model shown in Figure 9 . The data suggest that Muc1 functions to promote PyV MT signaling mediated by c-Src activation.
Results

c-Src levels are increased in the MT and MMT tumors
We have previously shown that MMTV-PyV MT transgenic mice exhibit a significant delay in tumor progression and a trend toward decreased metastasis when bred onto a Muc1 knockout background. To understand the mechanism by which Muc1 affects PyV MT-induced tumorigenesis, we examined the effect of Muc1 expression on c-Src. The intracellular tyrosine kinase, c-Src, plays a pivotal role in mediating the oncogenic effects of the PyV MT antigen. As described in Table 1 , the mouse models used in this study include MMTV-PyV MT transgenic mice either on a wild-type background (MT) or a Muc1 knockout background (MTK). We also crossed the MMTV-PyV MT mice with mice expressing the human MUC1 transgene on a mouse Muc1 wild-type background to generate MMT bitransgenics. Normal mammary glands from agematched wild-type mice were used as controls for PyV 
Muc1 and c-Src colocalize in the MT tumors
To further verify the interaction between c-Src and Muc1 and to determine the location of this complex, we used confocal microscopy to analyse Muc1/c-Src localization. Mammary tumors from MT mice were stained with antibodies to Muc1 (green) and c-Src (red). Muc1 was localized to the apical membrane while c-Src was localized throughout the cell membrane and throughout the cytoplasm. An overlay of their staining patterns revealed that they are colocalized mainly at the apical membrane ( Figure 3 ).
Determining the effect of Muc1 on c-Src activity
We next investigated the effect of the Muc1/c-Src interaction on PyV MT-mediated transformation. We proposed two mechanisms by which Muc1 could promote tumorigenesis. One is that Muc1 may directly influence c-Src kinase activity and promote c-Src activation by inducing conformational changes or recruiting c-Src activating molecules. Alternatively, Muc1 may influence c-Src signaling by promoting its association with downstream signaling molecules.
We investigated the first mechanism where Muc1 could influence PyV MT-induced tumorigenesis by regulating c-Src activity. In order to address the question of whether Muc1 modulates c-Src kinase activity, we compared c-Src activity in the hyperplastic glands from MT mice (n ¼ 6) with hyperplastic glands from MTK mice (n ¼ 6), which lack Muc1. The activity of c-Src immunoprecipitated from mouse mammary glands was measured by [ 32 P]ATP incorporation into a peptide substrate. As a control for the amount of c-Src, duplicate immunoprecipitations were carried out and assayed by immunoblotting for c-Src. Densitometry of the c-Src blots was used to normalize the kinase activity to the amount of immunoprecipitated c-Src. We compared c-Src kinase activity in (MT and MTK samples) at the initial stages of tumorigenesis when mice were 8 weeks of age. It may be that the presence of Muc1 plays a role at the initial stages of tumorigenesis, hence we might see a greater difference in c-Src kinase activity between MT and MTK mice at an earlier time point. We did not observe a significant difference in c-Src kinase activity between the hyperplastic glands of MT and MTK mice (data not shown). These observations suggest that the delayed tumorigenesis was not a consequence the inability of Muc1 to functionally activate c-Src tyrosine kinase. As such, we ruled out the first suggested mechanism for the role of Muc1 in PyV MT signaling, that of direct activation.
Muc1 expression promotes the association between c-Src and b-catenin
We determined the effect of Muc1 on several signaling pathways downstream of c-Src. We directed our efforts toward analysis of c-Src downstream signaling pathways in the presence or absence of Muc1. Among the c-Src substrates that we investigated is b-catenin. b-catenin is a component of the E-cadherin-mediated cell-cell junctions. The tyrosine phosphorylation of b-catenin by c-Src has been shown to inhibit the binding of b-catenin to E-cadherin, disrupt cell-cell adhesions, and promote cancer cell invasion. We investigated the association between c-Src and b-catenin in the hyperplastic glands from MT and MTK mice by immunoprecipitation for c-Src. Blotting for b-catenin revealed an increased association between c-Src and b-catenin in the presence of Muc1 (Figure 4 ). Only one MTK gland (3.14.3) showed a c-Src/b-catenin association that was comparable to Muc1-containing MT glands.
Muc1 expression does not decrease the association of b-catenin and E-cadherin
Since Muc1 affects b-catenin interactions in PyV MTinduced tumors, we were interested in determining whether Muc1 expression would influence the association between b-catenin and E-cadherin. To address this question, we immunoprecipitated b-catenin from tumors from MT, MMT, and MTK mice and immunoblotted for E-cadherin to assay for b-catenin/Ecadherin association. According to the model proposed by Kufe and co-workers (Li et al., 1998) , we expected to see decreasing b-catenin/E-cadherin association in the tumors from MMT and MT mice compared to tumors from MTK mice. However, we saw no difference in the level of b-catenin/E-cadherin association between tumors from MT and MTK mice ( Figure 5 ). This likely reflects differences between the interactions influencing 
Hyperplastic MT glands expressing Muc1 have higher levels of activated Stat3 than MTK glands
Stat3 activation is a known downstream event of c-Src signaling. Stat3 is activated in a wide variety of human tumors, where it is known to enhance tumor cell proliferation and prevent apoptosis (Calo et al., 2003) . MT and MTK mice were analysed at 8 weeks of age when the mammary glands are hyperplastic but not frankly tumorigenic. Using an antibody specific to the activated form of Stat3 (anti-phospho-Stat3 Y705), we observed higher levels of activated pStat3 in the MT mice compared with the MTK mice ( Figure 6 ). Muc1 expression may be enhancing the activation of Stat3, possibly by its association with EGFR and c-Src, which have been shown to increase Stat3 activation.
c-Src associates with the p85 subunit of PI3K only in the presence of Muc1
The p85 subunit of PI3K is among the key signaling molecules that associate with the PyV MT antigen (Talmage et al., 1989; Freund et al., 1992) . Activation of PI3K signaling influences cell proliferation, growth, survival, and cytoskeletal organization (Whitman et al., 1985; Courtneidge and Heber, 1987; Cantley, 2002) . Binding of p85 to the PyV MT antigen is a necessary event for PyV MT-induced tumorigenesis and may stimulate cell survival (Webster et al., 1998) . The association between c-Src and the p85 subunit of PI3K is thought to modulate the localization of activated c-Src at the cell membrane (Fincham et al., 2000) . We investigated whether the presence of Muc1 influenced the interaction of Src with p85. The interaction between c-Src and the p85 subunit of PI3K kinase was evident only in the hyperplastic glands from 8-week-old MT mice and not in the MTK mice ( Figure 7 ). However, we did not observe changes in pAkt, a downstream target of p85 signaling between MT and MTK samples (data not shown). The presence of Muc1 facilitates the interaction between c-Src and p85, and as such may promote tumor progression in the MT transgenic mice.
Muc1 directly associates with FAK and can influence c-Src localization
The intracellular localization of c-Src is critical for mediating its downstream signaling effects. In light of the fact that the presence of Muc1 was associated with enhancing c-Src interaction with its downstream targets, we next investigated the effect of Muc1 on c-Src localization. One substrate of c-Src is the focal adhesion kinase (FAK), which is localized to focal adhesions at the cell surface. Immunoprecipitation for FAK in tumor samples from MT and MTK mice revealed that Muc1 was in a complex with FAK ( Figure 8a ). Association of Muc1 with FAK and c-Src could promote peripheral localization of c-Src, which could then more readily activate FAK.
To better understand the effect of Muc1 expression on c-Src localization, we generated primary epithelial cell cultures derived from the hyperplastic glands of MT, MTK, and MMT mice. The epithelial lineage of the different cell lines was confirmed by expression of pancytokeratin, a marker of epithelial differentiation (data not shown). c-Src localization was determined by confocal microscopy. Immunofluorescent staining was used to compare the localization of c-Src in the MT, MMT, and MTK cells. Activated c-Src is normally localized at the cell membrane and cytoplasmically. A large proportion of the MTK cells exhibited perinuclear localization where c-Src formed a ring around the nucleus of the cell. Such a pattern was less observable in the MT and MMT cells (Figure 8b ), suggesting that Muc1 may play a role in the localization of c-Src at the plasma membrane.
Discussion
We analysed MMTV-PyV MT mammary tumors on a Muc1 wild-type background compared with tumors of MMTV-PyV MT mice on a Muc1 null background to specifically delineate the effect of Muc1 on PyV MT- Muc1 and c-Src interact in MMTV-PyV MT mouse model A Al Masri and SJ Gendler induced mammary tumorigenesis. We identified an in vivo association between Muc1 and c-Src in PyV MT-induced tumors, which falls in line with previous in vitro studies and thus substantiates a physiological relevance for the association (Li et al., 2001a) . Src phosphorylates the cytoplasmic tail of MUC1 at the Y46 within the YEKV site, which constitutes a consensus SH2 binding site for Src (Li et al., 2001a) . The SH3 domain of Src has also been shown to be involved in mediating the interaction with MUC1 (Li et al., 2001a) . Interestingly, it has been demonstrated that the intracellular targeting of c-Src is a kinaseindependent mechanism and rather relies on its SH3 domain with some modulation from the SH2 domain (Kaplan et al., 1994) . As such, the binding of c-Src to MUC1 could serve to regulate the intracellular targeting of c-Src, which is critical to its functioning at the cell membrane.
We hypothesized that the influence of Muc1 on PyV MT-induced tumorigenesis could be to increase c-Src activity. We assessed the effect of Muc1 expression on c-Src activity by carrying out c-Src kinase assays on tumors from MMT, MT, and MTK mice and observed no significant effect of MUC1/Muc1 expression levels on c-Src activity. This result is perhaps not surprising, given previous results that showed that the associated kinase activities in mammary tumors of PyV MT mutants decoupled from either the Shc or the PI3K signaling pathways were comparable to that of wild-type PyV MT (Webster et al., 1998) . The failure to observe a significant difference in Src activity in the absence of Muc1 could simply result from the heterogeneity of the tumor samples and the elevated Src kinase activity in the tumors, whereby subtle changes in Src activity could pass undetected. Despite the high levels of expression of c-Src and Muc1 in the MT-induced tumors, only a fraction of both are associated, which could provide an explanation for the lack of detectable differences in c-Src activity. Alternately, these results could indicate that Muc1 influences PyV MT-induced tumorigenesis through an alternative mechanism, such as promoting the association of c-Src with its substrate proteins.
Examination of hyperplastic glands from MMTVPyV MT glands on a Muc1 wild-type or Muc1 null background established that Muc1 does indeed influence the association of c-Src with known substrates. The presence of Muc1 in MT-induced tumors promoted the association between c-Src and b-catenin. Tyrosine phosphorylation of b-catenin by c-Src at Y654 has been shown to disrupt the binding of b-catenin to E-cadherin (Roura et al., 1999) . However, analysis of tumors from MT and MTK mice did not reveal a substantial change in the amount of b-catenin in association with Ecadherin, suggesting an alternate mechanism for weakening cadherin-dependent adhesions in PyV MT tumors.
We also observed increased levels of activated pStat3, a downstream target of c-Src activation, in the presence of Muc1. Muc1 may be enhancing the activation of Stat3, possibly by its association with both EGFR and c-Src, which have been shown to activate Stat3 (Olayioye et al., 1999) . Stat3 is involved in promoting cell cycle progression and cellular transformation and preventing apoptosis (Bromberg et al., 1999; CatlettFalcone et al., 1999a, b; Turkson and Jove, 2000) . Some PyV MT tumors that lack Muc1 exhibit a decrease in Erk2 activation (data not shown). Activation of MAPK in association with MUC1 has been demonstrated in vitro and in the mammary glands of MMTV-MUC1 transgenic mice (Meerzaman et al., 2001; Schroeder et al., 2001 ). In addition, mammary gland tumors induced by overexpression of MUC1 showed increased Erk activation, and involuting MMTV-MUC1 mammary glands expressed higher levels of activated Erk2 (Schroeder et al., 2004) . Erk2 has been reported to play a critical role in mediating proliferation in breast cancer cells (Flury et al., 1997) . Increases in Stat3 and Erk2 Muc1 expression also stimulates the interaction between c-Src and p85 in the hyperplastic glands of MT mice. The interaction of PyV MT with p85 is a key event in PyV MT-induced transformation (Whitman et al., 1985; Courtneidge and Heber, 1987) . Activation of PI3K signaling influences many aspects of cell behavior including proliferation, growth, survival, and cytoskeletal organization (Cantley, 2002) . Mutation of the p85 binding site on PyV MT hindered its capacity to induce tumors in animals (Talmage et al., 1989; Freund et al., 1992) . In a previously published study, transgenic mice expressing a mutated form of PyV MT decoupled from p85 binding developed mammary epithelial hyperplasias that were highly apoptotic, suggesting that PyV MT binding to p85 affected cell survival (Webster et al., 1998) . The analysis of MT and MTK glands did not reveal changes in the activation of Akt, a downstream target of PI3K signaling affecting cell growth and cell survival. Also, hyperplasias and tumors from MT and MTK mice did not exhibit a difference in the rate of apoptosis, suggesting that this may not be the major pathway affected by the lack of Muc1 expression (unpublished data). In addition to influencing growth and survival, PI3K mediates activation of the Rac GTP binding protein, which plays a major role in remodeling the actin cytoskeleton (Rodriguez-Viciana et al., 1997) . The p85 subunit of (PI3K) is also among the well-characterized c-Src interacting partners. The association between c-Src and the p85 subunit of PI3K is thought to modulate the localization of activated c-Src at the cell membrane (Fincham et al., 2000) . As such, the presence of Muc1 may be influencing the localization of c-Src at the cell membrane through modulating its association with p85. This is supported by the translocation to the plasma membrane of c-Src in MT-and MMT-derived epithelial cells as compared to MTK.
Finally, we demonstrate a novel association between Muc1 and a known Src substrate, FAK, in the PyV MT tumors, which potentially promotes the peripheral targeting of activated c-Src. FAK is a nonreceptor protein-tyrosine kinase localized within focal adhesions where the cytoskeleton interacts with the extracellular matrix via integrin receptors. FAK plays an important role in integrin-mediated signaling and in modulating processes such as cell growth, differentiation, survival, and migration (Hanks et al., 2003) . Following activation by c-Src phosphorylation, FAK interacts with a number of downstream signaling molecules including the adapter protein Grb2 and the p85 subunit of PI3K (Schlaepfer et al., 1999) . The binding of MUC1 to Src can help localize the kinase at the cell periphery where it can be in close proximity to target molecules such as b-catenin, FAK, and p85. The interaction between MUC1 and FAK has not been described previously. Further investigation into the regulation of these associations will shed light on the role of MUC1, Src, and other proteins on invasion and metastases.
It has been established that Muc1 plays an important role in the progression of PyV MT-induced tumorigenesis. Our data provide insights into the possible mechanism for the significant delay in tumor progression that is observed in the absence of Muc1. We have shown that Muc1 levels have little effect on Src kinase activity. Instead, we suggest that the interaction of Muc1 with c-Src promotes its binding to downstream targets and influences its intracellular localization. Figure 9 represents a model for the possible ways Muc1 could influence c-Src signaling. As such, the ability of Muc1 to potentiate c-Src signaling could influence the proliferation and migration of tumor cells. Our understanding of the critical role of Muc1 signaling in PyV MT-induced oncogenesis will be invaluable in delineating the effects of MUC1 overexpression in human breast cancer.
Materials and methods
Transgenic mouse models
All studies were performed on the FVB strain of mice with either wild-type Muc1, transgenic human MUC1, or Muc1 knockout (described in Table 1 ). The generation of Muc1 knockout mice and the human MUC1 transgenics has been previously described (Spicer et al., 1995b; Rowse et al., 1998) . The MUC1 transgenic mice, initially generated on the C57BL/6 background, were congenic with the FVB background, as were the Muc1 À/À mice. To study the role of MUC1 in tumor formation, MMTV-PyV MT transgenic mice (a generous gift of Dr W Muller, McMaster University, Ontario) were crossed with Muc1 knockout mice or MUC1 transgenic mice.
Protein analysis
Thoracic mammary glands were prepared for protein analysis as previously described (Schroeder et al., 2004) .
Antibodies
CT2 is a hamster monoclonal antibody developed in-house, which recognizes the cytoplasmic tail of both human MUC1 and mouse Muc1. HMFG-2 and B27.29 are mouse monoclonal antibodies that recognize the tandem repeat of human MUC1. HMFG-2 was a kind gift of Dr Joyce Taylor-Papadimitriou (ICRF, London, UK). B27.29 and FITC-B27.29 were kindly provided by Biomira (Edmonton, Alberta, Canada). c-Src (sc-18) from Santa Cruz was used for immunoprecipitation and immunoblotting. The monoclonal anti-Src (2-17) used for immunofluorescence was a kind gift from Dr Sarah Parsons (University of Virginia Health System, Charlottesville). Commercial antibodies used were b-catenin H-102 used for immunoprecipitation (10 mg per immunoprecipitation) and bcatenin C-18 used for immunoblotting (both from Santa Cruz), dpErk1/2 (Sigma), pStat3, p85, FAK, and c-Myc (Upstate Biotechnology), pAkt (Cell Signaling), and E-cadherin (Zymed).
Immunofluorescence
Tissues were prepared for immunofluorescence as described previously (Schroeder et al., 2004) . The primary antibodies were used at the following dilutions: CT2 (1 : 200) and Src, 2-17 (1 : 1000). The nuclei were visualized using TO-PRO 3 from Molecular Probes (1 : 1000) and cytokeratin was stained using FITC-conjugated pan-cytokeratin antibody from Sigma used at 1 : 500.
In vitro kinase assay
Protein lysate (1 mg) from mammary gland tumors or normal mammary glands was used to immunoprecipitate Src as described above. An assay kit (Upstate Biotechnology) was used to measure Src kinase activity.
Conjugating CT2 to agarose beads
To avoid contamination with immunoglobulin heavy chain during immunoprecipitation, we used the Seize Primary Immunoprecipitation Kit (Pierce).
Generating primary cultures from mouse mammary glands
Primary mouse mammary epithelial cells were prepared from virgin mice. In brief, dissected mammary glands were minced with a razor blade, transferred to a plate containing 0.5 mM EDTA in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 1% glutamax, and 1% penicillin/streptomycin, and incubated on a shaker at 371C for 1 h. The tissue was then filtered through a 40 mm nylon mesh. The filtrate contained dissociated cells, which were collected by centrifugation at 2000 r.p.m. for 2 min. The cells were washed 
